Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4Y0 | ISIN: KYG0028A1085 | Ticker-Symbol: 8ZD
Frankfurt
27.06.25 | 09:59
1,060 Euro
-1,85 % -0,020
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ABBISKO CAYMAN LTD Chart 1 Jahr
5-Tage-Chart
ABBISKO CAYMAN LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,3940,47428.06.

Aktuelle News zur ABBISKO CAYMAN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ABBISKO CAYMAN Aktie jetzt für 0€ handeln
FrABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
DoABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS TO PRESENT UPDATED RESULTS FROM THE PHASE 2 STUDY OF IRPAGRATINIB IN COMBINATION WITH ...1
MoABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT ENROLLMENT OF OBSERVATIONAL STUDY FOR THE TREATMENT OF ACHONDROPLASIA1
20.06.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS2
18.06.ABBISKO-B (02256): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 18, 2025-
16.06.Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC61SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational...
► Artikel lesen
16.06.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING IN REGISTRATIONAL STUDY OF IRPAGRATINIB FOR HCC2
12.06.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ...3
12.06.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
12.06.ABBISKO-B (02256): ANNOUNCEMENT MADE PURSUANT TO RULES 13.51B(2) AND 13.51(2) OF THE LISTING RULES1
10.06.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES CHINA NMPA ACCEPTANCE OF NDA FOR PIMICOTINIB FOR THE TREATMENT OF TGCT1
05.06.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
29.05.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES RECEIPT OF US$85MN FROM MERCK IN CONSIDERATION FOR PIMICOTINIB (ABSK021) GLOBAL ...11
26.05.China's CDE grants breakthrough status approval to Abbisko's HCC therapy1
26.05.Abbisko Therapeutics Secures Breakthrough Therapy Designation For Irpagratinib In HCC Treatment1
26.05.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CDE APPROVAL OF BREAKTHROUGH THERAPY DESIGNATION FOR IRPAGRATINIB (ABSK011) OF ABBISKO THERAPEUTICS IN THE ...3
23.05.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ORAL PRESENTATION BY ABBISKO THERAPEUTICS ON RESULTS OF PIMICOTINIB IN TGCT FROM THE PHASE 3 MANEUVER STUDY ...1
22.05.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
20.05.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' CSF-1R INHIBITOR, PIMICOTINIB (ABSK021), HAS BEEN GRANTED PRIORITY REVIEW FOR TGCT ...2
16.05.ABBISKO-B (02256): FORM OF PROXY FOR THE 2024 ANNUAL GENERAL MEETING-
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1